Mimedx (MDXG) Gross Margin (2011 - 2026)

Mimedx (MDXG) reported Gross Margin of 70.56% for Q1 2026, down 1067.0% on a YoY basis from 7.3% in Q1 2025, and down 15.87% sequentially from 83.86% in Q4 2025.

Mimedx (MDXG) Gross Margin (2011 - 2026) Analysis & Trends

Mimedx (MDXG) has 16 years of Gross Margin data on file, last reported at 70.56% in Q1 2026.

  • For the quarter ending Q1 2026, Gross Margin fell 1067.0% year-over-year to 70.56%; the trailing twelve-month figure through Mar 2026 stood at 81.04% (down 90.0% YoY), and the FY2025 full-year result was 82.56%, down 22.0% from the prior year.
  • Gross Margin fell to 70.56% in Q1 2026, from 83.86% in the prior quarter.
  • In the past five years, Gross Margin ranged from a high of 84.67% in Q1 2024 to a low of 70.56% in Q1 2026.
  • A 5-year average of 81.85% and a median of 82.32% in 2022 frame the typical range for Gross Margin.
  • Across the five-year window, Gross Margin jumped 338 bps in 2023 and sank 1067 bps in 2026, its largest moves.
  • Tracing MDXG's Gross Margin over 5 years: stood at 80.68% in 2022, then climbed by 4 bps to 84.06% in 2023, then retreated by 3 bps to 81.8% in 2024, then climbed by 3 bps to 83.86% in 2025, then slipped by 16 bps to 70.56% in 2026.
  • Business Quant data shows MDXG's Gross Margin at 70.56% in Q1 2026, 83.86% in Q4 2025, and 83.54% in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Gross Margin (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - -
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn 88.95%
4 NuCana 279.75 Bn 279.75 Bn - -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn 86.85%
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn 91.79%
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn 90.68%
9 Revolution Medicines 37.78 Bn 37.78 Bn - -
10 Mimedx 615.09 Mn 455.31 Mn 41.62 Mn 70.56%

Historic Data

Download Data
DateValue
Mar 31, 2026 70.56%
Dec 31, 2025 83.86%
Sep 30, 2025 83.54%
Jun 30, 2025 81.05%
Mar 31, 2025 81.23%
Dec 31, 2024 81.80%
Sep 30, 2024 81.77%
Jun 30, 2024 82.97%
Mar 31, 2024 84.67%
Dec 31, 2023 84.06%
Sep 30, 2023 81.90%
Jun 30, 2023 83.28%
Mar 31, 2023 82.67%
Dec 31, 2022 80.68%
Sep 30, 2022 81.99%
Jun 30, 2022 82.32%
Mar 31, 2022 83.13%
Dec 31, 2021 86.03%
Sep 30, 2021 83.94%
Jun 30, 2021 81.28%